| [1] |
National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Breast cancer. Version 2.2015 [EB/OL]. [2015-04-20]. http:/ /www. nccn. org/professionals/physician_gls/f_guidelines.asp#breast.
|
| [2] |
孙强.乳腺癌新辅助化疗的实践与思考[J/CD]. 中华乳腺病杂志:电子版,2011,5(3):266-271.
|
| [3] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol,2008,26(5):778-785.
|
| [4] |
Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups[J].J Clin Oncol,2011,29(25):3351-3357.
|
| [5] |
Sulpher J, Dent R, Dent S. Neoadjuvant chemotherapy in breast cancer: what questions remain? [J]. Curr Opin Support Palliat Care,2014,8(1):59-63.
|
| [6] |
de Azambuja E, Holmes AP, Piccart-Gebhart M, et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised,open-label, multicentre, phase 3 trial and their association with pathological complete response [J]. Lancet Oncol,2014,15(10):1137-1146.
|
| [7] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938):164-172.
|
| [8] |
Berruti A, Amoroso V, Gallo F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a metaregression of 29 randomized prospective studies[J]. J Clin Oncol,2014,32(34):3883-3891.
|
| [9] |
Sikov WM. Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting[J]. Gland Surg,2014,3(1):81-84.
|
| [10] |
von Minckwitz G,Kümmel S,Vogel P,et al. Neoadjuvant vinorelbinecapecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase Ⅲ randomized GeparTrio trial [J]. J Natl Cancer Inst,2008,100(8):542-551.
|
| [11] |
Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol,2002,20(6):1456-1466.
|
| [12] |
von Minckwitz G, Blohmer JU, Costa SD, et al. Responseguided neoadjuvant chemotherapy for breast cancer[J]. J Clin Oncol,2013,31(29):3623-3630.
|
| [13] |
Coudert B, Asselain B, Campone M,et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial[J]. Oncologist, 2012,17(7):900-909.
|
| [14] |
邵志敏, 余科达. 乳腺外科的发展趋势[J]. 中国普外基础与临床杂志,2007,14(3):252-254.
|
| [15] |
Kaufmann M, Hortobagyi GN, Goldhirsch A. Recommendations from an international expert panel on the use of neoadjuvant(primary) systemic treatment of operable breast cancer: an update[J]. J Clin Oncol,2006,24(12):1940-1949.
|